Pfizer COVID vaccine likely to get approval for 12-15 group next week

The U.S. Food and Drug Administration is expected to authorize Pfizer’s COVID-19 vaccine for those between 12 and 15 years old.

The final OK will likely come next week.

The Pfizer shot is a two-dose COVID-19 vaccine, which has been widely used with little side effects over the last five months.

A federal official, speaking with the AP on condition of anonymity, said the agency was expected to expand its emergency use authorization for Pfizer’s two-dose vaccine by early next week, and perhaps even sooner.

In March, Pfizer began a vaccine study of 12-15 year olds.

It would be the first major expansion of vaccine eligibility across the U.S. since it’s initial use authorization.